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Introduction
The vast majority of cells are, or have the potential to be, polar-
ized. Polarity requires the ability to control the protein composi-
tion of the plasma membrane in time, location, and in response 
to signaling pathways. A well-studied example is epithelial cells 
that have compositionally distinct apical and basolateral mem-
branes. In addition to composition, cells regulate their morphol-
ogy, for example the apical surface of epithelial cells is usually 
studded with microvilli. Cell morphology, as well as aspects of 
endocytosis, exocytosis, and membrane signaling are integrated 
processes, yet relatively little is known about how this is achieved. 
Part of this integration is provided by the actin-based cytoskele-
ton that is intimately associated with the plasma membrane.   
We have been studying in detail the microfilaments that support 
microvilli on epithelial cells as a model system to uncover how 
these processes are controlled and integrated. Here we report on 
mechanisms that regulate the presence of microvilli on cells.
Epithelial cell microvilli consist of a core of bundled actin 
filaments tethered laterally to the plasma membrane in part by ezrin, 
a member of the ERM (ezrin/radixin/moesin) family of regulated 
membrane cytoskeleton linking proteins (Fehon et al., 2010). 
Ezrin can exist in a dormant-inactive form in which its C-terminal 
F-actin binding site as well as binding sites for membrane- 
associated proteins on its N-terminal FERM (4.1 ERM) domain 
are masked by their intramolecular association. Upon activation 
by phosphorylation, the FERM domain can bind the cytoplasmic 
tails of various transmembrane proteins, or to the PDZ (post-
synaptic density 95/discs large/zona occludens-1) domain contain-
ing scaffolding protein EBP50 (ERM-binding phosphoprotein 
of 50 kD). The EBP50 protein family, also known as the NHERF 
(Na
+-H
+ exchanger regulatory factor) family (Shenolikar et al., 
2004), includes E3KARP (NHERF2) and PDZK1 (NHERF3), and 
together represent the only known PDZ scaffolding proteins 
present in the apical aspect of polarized epithelial cells, and 
have been suggested to coordinate functions in the apical do-
main. In addition, a broader role for EBP50, and the impor-
tance of its apical localization, is emerging in tumorigenesis 
(Georgescu et al., 2008).
We initially identified EBP50 as a protein that binds active, 
but not dormant, ezrin (Reczek et al., 1997). It contains two PDZ 
domains followed by a tail whose last 38 residues associate with 
ezrin’s N-terminal FERM domain. EBP50 was independently 
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Mice lacking either ezrin or EBP50 have short aberrant 
microvilli on their epithelia, suggesting that the two proteins 
function together in microvillus structure or regulation (Morales 
et al., 2004; Saotome et al., 2004). Consistent with this, we have 
shown that siRNA knockdown of EBP50 in human chorio-
carcinoma JEG-3 cells, which are normally robustly covered   
in microvilli, results is a significant reduction of cells with   
microvilli (Hanono et al., 2006). Expression of an RNAi-resistant 
GFP-EBP50 construct maintains microvilli when endogenous 
EBP50 is knocked down (LaLonde et al., 2010). This pro-
vides an assay to explore properties of EBP50 that are necessary 
for maintaining microvilli. Here we use this in vivo system, 
coupled with biophysical studies and biochemical characteriza-
tion of EBP50 variants, to show that both its function in micro-
villi and biochemical scaffolding properties are regulated by 
phosphorylation. Our biochemical analysis of purified wild-type 
and mutant EBP50 reveal that it is an elongated monomer in 
solution  with  no  tendency  to  oligomerize  regardless  of  its 
phosphorylation state.
Results
EBP50 is required for microvillar assembly 
in JEG-3 cells
Microvilli  are  dynamic  structures  with  life  cycles  averaging 
around 12 min and involving assembly, steady-state length, and 
retraction phases (Gorelik et al., 2003; unpublished data).   
Depletion of EBP50 by siRNA in human choriocarcinoma JEG-3 
cells causes a significant loss of cells displaying apical micro-
villi as visualized by ezrin and actin staining (Hanono et al., 2006). 
discovered as a factor necessary for conferring protein kinase A 
(PKA) regulation on NHE3 (Na
+-H
+ exchanger 3), hence the   
alternative name NHERF1 (Weinman et al., 1995). It has subse-
quently been implicated in scaffolding and regulating membrane 
proteins such as CFTR (cystic fibrosis transmembrane conduc-
tance regulator), NaPi IIa cotransporter, and the 2-adrenergic 
receptor (Short et al., 1998; Cao et al., 1999; Hernando et al., 2002). 
In addition to binding integral membrane proteins, EBP50 has 
been shown to bind the RabGAP protein EPI64 (EBP50-PDZ 
interactor of 64 kD), the RhoGAP nadrin through its first PDZ 
domain (Reczek and Bretscher, 2001), and PDZK1 through   
either domain (LaLonde et al., 2010).
EBP50 is subject to phosphorylation by several kinases, and 
these modifications have been suggested to alter its binding acti-
vity and possibly its oligomeric state. The G protein–coupled   
kinase, GRK6A, phosphorylates EBP50 on serine 290 (Hall et al., 
1999), and this is reported to increase its oligomerization (Lau and 
Hall, 2001). The phosphorylation of serines 162, 339, and 340 by 
PKC is also thought to promote oligomerization of EBP50 as well 
as increase its affinity for PDZ ligands (Raghuram et al., 2003; 
Fouassier et al., 2005; Li et al., 2007). During mitosis EBP50 is 
phosphorylated on serines 280 and 302 by the cyclin-dependent 
kinase Cdc2, and this phosphorylation is reported to inhibit oligo-
merization (He et al., 2001). Some of these studies suggesting reg-
ulation of oligomerization have used blot overlays (Fouassier   
et al., 2000; Shenolikar et al., 2001) and were not aware of the 
ability of the EBP50 tail to bind PDZ2 in an intramolecular man-
ner (Morales et al., 2007; Cheng et al., 2009). However, recent 
work on wild-type EBP50 suggests that it exists as a monomer in 
solution (Li et al., 2007, 2009).
Figure 1.  Depletion of EBP50 by siRNA causes a defect in microvilli formation. JEG-3 cells were treated with siRNA against luciferase as a control (A–C) 
or against EBP50 (D–F) and examined by scanning electron microscopy (SEM; A, B, D, and E) or confocal microscopy by ezrin staining (C and F). Low 
and high magnification SEM images were acquired at 4,000 and 20,000x, respectively. Control cells showed numerous microvilli, whereas siEBP50 cells 
showed a dramatic reduction in microvilli by both SEM and ezrin staining. Confocal images were processed to be shown at the same scale as the high 
magnification SEM micrographs.399 Phospho-regulation of microvilli by EBP50 • Garbett et al.
elements of EBP50 necessary to maintain microvilli in EBP50 
knockdown cells. We first made and characterized mutations in 
EBP50’s tail specifically defective in binding the ezrin FERM 
domain, and then tested their function in vivo.
Structural analyses of the tail of EBP50 bound to the ra-
dixin (Terawaki et al., 2006) or moesin (Finnerty et al., 2004) 
FERM domain show that the C-terminal 12 amino acids form an 
-helix that associates with the FERM domain (Fig. 2 A). Structure- 
based mutations to reduce this interaction were made in an ex-
pression construct of MBP (maltose-binding protein) N-terminally 
fused to the C-terminal 39 residues of EBP50 (Fig. 2 A). The 
ability of immobilized ezrin FERM domain to retain soluble 
EBP50 tail fusion constructs was then assessed (Fig. 2 B). Dele-
tions of either the C-terminal 17 residues (EBP50-320-341), or 
the four terminal residues of EBP50 (FSNL), or even just the 
terminal leucine (L), abolished the binding to the ezrin FERM 
domain. Other critical residues in the -helix necessary for inter-
acting with the FERM domain are methionine 346, tryptophan 
348, and phenylalanine 355 (Terawaki et al., 2006), and both the 
F355R  and  M346A/W348A  mutations  also  abolished  inter-
action with the ezrin FERM domain. Surprisingly, the F355A mu-
tation only had a modest negative effect on binding ezrin FERM 
under these conditions. Additionally, EBP50 can form an intra-
molecular association between its C-terminal FSNL sequence 
and its second PDZ domain (Morales et al., 2007). Addition of a 
single alanine to the C terminus abolishes the ability of the tail to 
bind its own PDZ2 domain, but this had little effect on the EBP50 
tail–ezrin FERM interaction.
The EBP50 tail mutations were introduced into an RNAi-
resistant GFP-EBP50 construct and expressed in siEBP50-treated 
JEG-3 cells (Fig. 3 and Fig. S1 A). Expression levels of each 
GFP-EBP50 construct were similar to normal endogenous EBP50 
levels, and in siEBP50-treated cells were three- to fourfold 
To determine if this was due to a defect in a particular phase of 
the microvillar life cycle, we examined JEG-3 cells treated with 
either control siRNA–targeting luciferase or siRNA against 
EBP50 (siEBP50) by scanning electron microscopy (Fig. 1).
In siEBP50-treated cells the apical surface is smooth and shows 
no evidence of small microvillar protrusions, suggesting that 
loss of EBP50 prevents the assembly phase of microvilli (Fig. 1, 
D and E). Comparison of ezrin staining by confocal microscopy 
at the same final magnification shows that ezrin localization is 
as good as scanning electron microscopy at identifying surface 
microvilli (Fig. 1, C and F). Therefore, to explore in more depth 
the possibility that EBP50 loss might reduce both the number 
and lifetime of microvilli, we prepared cells expressing ezrin-
GFP treated with control siRNA or siEBP50 and imaged them 
in an environmental chamber for 20–30 min, taking confocal 
stacks every 30 s (Videos 1 and 2, respectively). Control cells 
showed numerous dynamic microvilli, whereas the siEBP50 
treated cells were essentially featureless. Occasionally small 
punctuate ezrin-GFP structures formed only to disappear very 
quickly, suggesting that EBP50 is required to assemble micro-
villi. As noted previously, microvilli above junctions are often 
resistant to siEBP50 treatment (Fig. 1 and Video 2; Hanono   
et al., 2006). Examination of these structures by both scanning 
electron microscopy and confocal microscopy of ezrin staining 
(Fig. 1, A–F) again showed that the latter technique accurately 
reflects the presence of microvilli on these cells.
EBP50 requires an ezrin binding site  
and a functional PDZ1 domain for  
microvilli assembly
Loss of microvilli in siEBP50-treated cells is reversed by ex-
pression  of  an  RNAi-resistant  GFP-EBP50  (LaLonde  et  al., 
2010). We exploited this system to systematically determine the 
Figure 2.  Mutations in the tail of EBP50 per-
turb binding to ezrin. (A) Schematic of MBP-
EBP50  tail  (320–358)  constructs,  with  the 
-helical  region  that  interacts  with  the  ERM 
FERM  domain  indicated.  Mutations  or  trun-
cations were made in the tail of EBP50 that 
alter  or  remove  key  residues  necessary  for 
interaction with ezrin based on known struc-
tures. The additional alanine shown in red was 
added in the EBP50-LA construct to inhibit the 
tail–PDZ2 interaction. (B) Ezrin FERM coupled 
to CNBr-agarose was used to recover soluble 
MBP-EBP50  tails  with  indicated  mutations/
truncations. Gels were stained for total protein 
with IRDye.JCB • VOLUME 191 • NUMBER 2 • 2010   400
because it can no longer bind to EPI64, we generated a chimera 
of EPI64 fused to the last 60 residues of EBP50 that directly 
links EPI64 to ezrin, effectively bypassing EBP50. When this 
chimera was expressed in siEBP50-treated cells it was unable to 
restore microvilli (Fig. S2). In cells that still had a few remain-
ing microvilli the chimera localized exclusively to the base of 
microvilli (Fig. S2 B), which is where endogenous EPI64 has 
been shown to localize (Hanono et al., 2006). Therefore, an in-
ability to bind EPI64 is unlikely to be the only reason mutation 
of PDZ1 prevents EBP50 from forming microvilli.
Cell cycle–regulated phosphorylation of 
EBP50 inhibits its function in interphase, 
but not mitotic, cell microvilli
As introduced earlier, EBP50 is subject to phosphorylation on 
multiple sites by several different kinases, so we set out to eval-
uate the role of these modifications by each kinase in microvilli 
formation. The kinase GRK6A phosphorylates rabbit EBP50 on 
serine 289 (serine 290 in human EBP50) and is responsible for 
75% of the constitutive levels of EBP50 phosphorylation (Hall 
et al., 1999). We generated mutations in human EBP50 in both 
serine 290 and the adjacent serine 291 to either alanine or aspar-
tate to mimic nonphosphorylated and phosphorylated forms of 
EBP50,  respectively.  These  phospho-deficient  and  -mimetic 
mutants of GFP-EBP50 were expressed in cells depleted of en-
dogenous EBP50 and scored for their abilities to form microvilli 
(Fig. S3). Interestingly, both the phospho-deficient and -mimetic 
mutants of EBP50 were able to maintain microvilli in siEBP50-
treated cells (Fig. S3, A and B), indicating that phosphorylation 
of EBP50 by GRK6A has no effect on microvilli assembly   
or maintenance.
During the early stages of mitosis in HeLa cells, Cdc2 
phosphorylates  EBP50  on  serine  residues  280  and  302  (He   
et al., 2001). To investigate potential regulation by Cdc2, we 
generated phospho-mimetic and -deficient mutants of these ser-
ine residues and determined their ability to maintain microvilli 
in siEBP50-treated cells (Fig. 5, A and B and expression levels: 
Fig. S1 B). The phospho-deficient mutant was able to maintain 
microvilli at levels indistinguishable from wild type, whereas 
the phospho-mimetic mutant was unable to restore microvilli 
(Fig. 5, A and B). To determine if EBP50 phosphorylation by 
Cdc2 also causes a defect during the formation of microvilli, we 
coexpressed ezrin-GFP and a TagRFPT-tagged version of the 
Cdc2 site phospho-mimetic EBP50 in cells treated with siEBP50 
and found that similar to cells depleted of EBP50 or expressing 
a PDZ1 mutant, microvilli were unable to form (Video 5). Thus, 
phosphorylation of EBP50 by Cdc2 inhibits its role in microvillar 
assembly in interphase cells.
Because mitotic cells are generally covered in small micro-
villi (Sanger and Sanger, 1980), we explored whether EBP50 
becomes  phosphorylated  during  mitosis  in  JEG-3  cells,  and 
whether EBP50 is needed for mitotic cell microvilli. To exam-
ine if EBP50 becomes phosphorylated in mitosis, JEG-3 cells 
were arrested at prometaphase after incubation with 50 ng/ml 
nocodazole for 18 h, and then allowed to progress through mitosis 
by washout with full media. As is seen in HeLa cells, upon   
nocodazole arrest EBP50 becomes highly phosphorylated and 
higher than the residual endogenous protein (Fig. S1 A). About 
68% of JEG-3 cells normally show abundant microvilli on their 
apical surface, and when EBP50 levels are reduced 70% by 
siRNA treatment the number of cells with microvilli is reduced 
to 23% as assessed by ezrin and F-actin localization (Fig. 3,   
A and B; Fig. S1 A). As we have noted earlier (Hanono et al., 
2006), and as can be seen in Fig. 1, D–F and Fig. 3 B, microvilli 
immediately above cell–cell junctions are especially resistant to 
EBP50 knockdown and these are not considered when counting 
cells  lacking  microvilli.  Expression  of  RNAi-resistant  GFP-
EBP50 restored microvilli in 50% of the cells, whereas ex-
pression of a control plasmid expressing a GFP protein targeted 
to the nucleus (GFP-Nuc) did not. Expression of all constructs 
harboring mutations that abolish the EBP50–ezrin interaction 
failed to restore microvilli (Fig. 3, A and B and equivalent ex-
pression  levels:  Fig.  S1 A).  Surprisingly,  the  EBP50-F355A 
mutant, which is still able to bind the ezrin FERM, was unable 
to restore microvilli perhaps for some other reason, as it was 
unable to incorporate into microvilli even in the presence of en-
dogenous EBP50 (unpublished data). Interestingly, inhibition 
of the EBP50 intramolecular interaction in the EBP50-LA mu-
tant was fully competent to form microvilli. Thus, the interaction 
of EBP50 with ezrin is critical for the presence of microvilli on 
JEG-3 cells.
To investigate the roles that EBP50’s PDZ domains play in 
microvilli maintenance, the conserved GYGF motif in the be-
ginning of each PDZ domain was mutated to GYAA to specifi-
cally abolish binding to PDZ ligands (Doyle et al., 1996). The 
single and double PDZ mutants were expressed in cells treated 
with siEBP50 at levels 3–6 times higher than residual endoge-
nous levels, and their ability to maintain microvilli was assayed 
as before (Fig. 4 and expression levels: Fig. S1 B). A truncated 
form of EBP50 containing only the last 39 amino acids of the 
tail, which is able to bind ezrin but lacks PDZ domains (Fig. 2), 
was unable to restore microvilli (Fig. 4 A) despite the fact that it 
localizes to microvilli in nonsiRNA-treated cells (unpublished 
data), suggesting that EBP50 isn’t merely binding to ERMs to 
keep them in their open active conformation. Constructs with 
both PDZ1 and PDZ2 mutated, or just PDZ1 mutated showed a 
loss of microvilli similar to the levels of the EBP50 tail alone 
(Fig. 4, A and B). Interestingly, cells expressing EBP50 with 
mutation of PDZ2 alone were able to form microvilli at levels 
indistinguishable from wild type. To determine if defects in PDZ 
binding were also causing defects during the assembly stage of 
microvilli, cells coexpressing ezrin-GFP and either RNAi-resistant 
TagRFPT-EBP50 wild-type or with both PDZ1 and 2 mutated 
were treated with siEBP50 and imaged for 7 min every 15 s   
(Videos 3 and 4, respectively). Cells expressing wild-type EBP50 
showed numerous microvilli at various stages in the microvillar 
life cycle, whereas cells expressing the EBP50 PDZ1/2 mutant 
showed no evidence of microvilli assembly. Collectively, these 
results indicate that EBP50’s ability to bind PDZ1 but not PDZ2 
ligands is critical for the assembly of microvilli.
We have shown that overexpressing a construct of EPI64 
that cannot bind the first PDZ domain of EBP50 causes a loss   
of microvilli (Hanono et al., 2006). To investigate whether 
the PDZ1 mutant of EBP50 is unable to assemble microvilli 401 Phospho-regulation of microvilli by EBP50 • Garbett et al.
Figure 3.  The EBP50–ezrin interaction is critical for microvilli. GFP-tagged RNAi-resistant mutants of EBP50 were expressed in EBP50 siRNA (siEBP50)–treated 
JEG-3 cells and their abilities to maintain microvilli were assayed. (A) Results from scoring cells for the presence of microvilli; error bars indicate mean ± SD.   
(B) Representative maximum projection images of the apical surface from the microvillar rescue assay. Top row was not treated with siEBP50, and shows control 
cells transfected to express the GFP-Nuc control plasmid. Cells were stained for ezrin (red) and actin (blue) and transfected cells identified as those expressing 
the GFP-tagged construct (green). Microvilli were visualized on the apical surface of cells by ezrin and phalloidin staining. Bar, 10 µm.JCB • VOLUME 191 • NUMBER 2 • 2010   402
enrichment in ezrin despite a loss of EBP50 staining and expres-
sion (Fig. 5 C and Fig. S4 C). These results indicate that EBP50 is 
heavily phosphorylated during mitosis by Cdc2 but this phosphory-
lation, although inhibitory in interphase cells, has no observable 
effect in mitotic cells, indicating that mitotic microvilli are struc-
turally and perhaps functionally distinct from those in interphase.
remains  heavily  phosphorylated  until  2–3  h  after  nocodazole 
washout (Fig. S4 A), and this phosphorylation can be largely abol-
ished by inhibition of Cdc2 with 2 µM roscovitine (Fig. S4 B;   
He et al., 2001). During mitosis JEG-3 cells are covered with dense 
short microvilli rich in ezrin and EBP50 (Fig. 5 C). Strikingly, 
upon siEBP50 treatment microvilli are unaffected, maintaining an 
Figure 4.  PDZ1 but not PDZ2 binding is required for microvilli. (A) Quantification of cells scored for the presence of microvilli; error bars indicate   
mean ± SD. (B) Representative images of the apical surface from the microvillar rescue assay. Cells were stained for ezrin (red) and actin (blue) and transfected 
cells identified as those expressing the GFP-tagged construct (green). Bar, 10 µm.403 Phospho-regulation of microvilli by EBP50 • Garbett et al.
Figure 5.  Phosphorylation by Cdc2 inhibits EBP50’s role in forming microvilli in interphase but not mitotic cells. (A) Results from scoring JEG-3 cells for 
the presence of microvilli; error bars indicate mean ± SD. (B) Representative images from the microvillar rescue assay. Cells were stained for ezrin (red) 
and actin (blue) and transfected cells identified as those expressing the GFP-tagged construct (green). Bar, 10 µm. (C) JEG-3 cells transfected with siRNA 
targeting EBP50 (siEBP50) or luciferase (siControl) were arrested in 50 ng/ml nocodazole overnight, fixed and stained for endogenous EBP50 (red), ezrin 
(green), and DNA (blue). Note the loss of EBP50 from microvilli of the cell cortex in siEBP50-treated cells, whereas ezrin localization remains unchanged. 
Bar, 5 µm.JCB • VOLUME 191 • NUMBER 2 • 2010   404
EBP50 is an elongated monomer 
regardless of its phosphorylation state
Our results show that EBP50 mutants with phospho-mimetic   
or -deficient mutations can affect its function in microvillar as-
sembly. Because it has been suggested, based on blot overlay 
experiments, coprecipitations out of cell lysates, and migration 
in sizing columns, that EBP50 may be capable of oligomeriz-
ing (Fouassier et al., 2000; Lau and Hall, 2001; Shenolikar et al., 
2001) and that phosphorylation of EBP50 plays a role in regu-
lating its oligomeric state (Lau and Hall, 2001; Fouassier et al., 
2005), we set out to determine the oligomerization state of 
EBP50 and whether it is affected in our EBP50 mutants. To   
purify recombinant EBP50, 6xHis-SUMO–tagged versions of 
wild-type and all the site-directed mutants were expressed   
in bacteria, purified on Ni
2+ resins, and the EBP50 was then 
cleaved off from the SUMO tag to recover highly pure un-
tagged EBP50 and its mutants (purification of wild-type is 
shown in Fig. S5). Wild-type EBP50 analyzed on a Superdex 
200 10/300 GL gel filtration column ran as a single population 
with a Stokes radius of 41 Å, which corresponds for a globular 
protein to a molecular weight of 100 kD (Fig. 8 A), a size 
similar to that reported earlier (Li et al., 2007; Morales et al., 
2007). The large Stokes radius suggests that it is either a dimer 
or a highly elongated monomer. As an independent method for 
examining its physical properties, the S value of EBP50 was 
determined by velocity sedimentation in sucrose gradients. 
Sedimentation together with standards of known S value indi-
cated a sedimentation coefficient of 2.7 S for EBP50 (Fig. 8 C). 
Using these two physical constants predicts a native molecular 
weight of 47 kD (Siegel and Monty, 1966). Furthermore, using 
the partial specific volume value for proteins of 0.74 cm
3/g, 
these data reveal a highly asymmetric protein with a frictional 
coefficient f/fo of 1.8 (a value of 1 represents a spherical protein, 
whereas a higher number is characteristic of an elongated mole-
cule), thereby accounting for its high Stokes radius and low 
sedimentation coefficient. Thus, EBP50 is an elongated mono-
mer in solution.
Analysis of EBP50 with mutations in either PDZ domain, 
especially to PDZ2, increased the Stokes radius slightly and de-
creased the S value, indicating the protein is still monomeric but 
becomes slightly more elongated (Fig. 8 C), consistent with the 
finding that the tail normally binds PDZ2 (Morales et al., 2007). 
Phospho-mimetic and -deficient mutations of either the Cdc2 or 
GRK6A phosphorylation sites did not affect the overall confor-
mation of EBP50 (Fig. 8 C). Interestingly, mutation of the PKC 
sites to either phospho-mimetic or -deficient forms resulted in a 
modest increase in Stokes radius of EBP50, similar to that seen 
with mutation of the second PDZ domain (Fig. 8 C), and similar 
to what has been seen before (Li et al., 2007).
Importantly, in none of the 11 EBP50 constructs analyzed 
by gel filtration and sucrose gradients, each of which was per-
formed at least twice, did we detect any evidence of EBP50 
oligomers. Additionally, no evidence of oligomerization was seen 
when all constructs were sized by blue-native PAGE (data not 
shown). Collectively, these results indicate that EBP50 is an elon-
gated monomer and phospho-mimetic mutations do not mediate 
its oligomerization.
Phosphorylation of EBP50 by PKC 
regulates its role in microvilli and 
contributes to microvillar organization
PKC phosphorylates EBP50 on serines 162 (Raghuram et al., 
2003), 339, and 340 (Fouassier et al., 2005), and this has been 
reported to result in an increased affinity for PDZ-binding li-
gands (Li et al., 2007). To determine if PKC plays any role in 
regulating EBP50 in microvillar formation, phospho-mimetic 
and -deficient point mutants were created at these serine resi-
dues and the control or mutant GFP-EBP50 constructs were ex-
pressed in JEG-3 cells treated with siEBP50, and their ability to 
preserve microvilli was assayed as before (Fig. 6 and expres-
sion levels: Fig. S1 B). Interestingly, both the phospho-deficient 
and -mimetic mutants were unable to maintain microvilli (Fig. 6, 
A and B). To determine if EBP50 phosphorylation by PKC also 
causes a defect during the formation of microvilli, we coex-
pressed ezrin-GFP and a TagRFPT-tagged version of the PKC 
site phospho-mimetic EBP50 in cells treated with siEBP50 and 
found that similar to cells depleted of EBP50 or expressing a 
PDZ1 mutant or Cdc2 site phospho-mimetic mutant, microvilli 
were unable to form (Video 6). Strikingly however, coexpres-
sion of both the phospho-mimetic and -deficient mutants was 
able to restore microvilli at levels indistinguishable from wild 
type (Fig. 6). Collectively, these results suggest that either the 
phosphorylation state of EBP50 mediated by PKC must cycle 
or that once phosphorylated by PKC, EBP50 engages in differ-
ent interactions than its non-PKC–phosphorylated form and 
that all of these interactions are required for microvilli for-
mation. In a small fraction of the cells coexpressing both the 
phospho-mimetic and -deficient mutants we noticed a clustering   
of microvilli, suggesting that PKC phosphorylation of EBP50 
may alter the arrangement of microvilli along the apical surface 
(Fig. 6 B, arrows).
To further explore the possible role of PKC in microvillar 
regulation, JEG-3 cells were serum starved overnight and then 
treated with 1 µM PMA for 30 min to activate PKC. Strikingly, 
treatment with PMA caused some cells to develop either dorsal 
ruffles or clusters of microvilli reminiscent of those we ob-
served with coexpression of the PKC site phospho-mimetic 
and -deficient EBP50 mutants (Fig. 7 A). These microvilli clus-
ters were enriched in both EBP50 and ezrin and were centered 
around a tight knot of actin in the terminal web region at the 
base of the microvilli. To determine if these microvilli clusters 
were a result of PKC phosphorylation of EBP50, we over-
expressed wild-type GFP-EBP50 or either the PKC phospho-
mimetic or -deficient mutant of EBP50 in cells treated with PMA 
(Fig. 7 B). Both the wild-type and PKC site phospho-mimetic 
constructs showed microvilli clusters in 20% of cells, whereas 
the  phospho-deficient  mutant  almost  completely  blocked   
microvilli clustering in PMA-treated cells (Fig. 7 C). The 
clustering of microvilli seen with the expression of the PKC 
phospho-mimetic  mutant  only  became  pronounced  with 
PMA treatment, indicating that in addition to EBP50, some 
other factor(s) need to be phosphorylated to induce micro-
villi clustering. Thus, phosphorylation of EBP50 by PKC, as 
well as other factors, leads to the rearrangement of microvilli 
into apical clusters.405 Phospho-regulation of microvilli by EBP50 • Garbett et al.
are not functional for microvillar formation in vivo. Addition-
ally, phospho-mimetics for the Cdc2 and PKC sites, and phos-
pho-deficient for the PKC sites, are also nonfunctional in vivo 
in terms of the microvilli maintenance assay, but the under-
lying reasons were not clear. We therefore explored in depth   
Cdc2 or PKC phosphorylation of EBP50 
inhibits ligand accessibility to PDZ1 when 
PDZ2 is occupied
Our results reveal that EBP50 is monomeric in solution, and 
that constructs with defects in ezrin binding or PDZ1 binding 
Figure 6.  Phosphorylation by PKC regulates EBP50’s ability to maintain microvilli. (A) Results from scoring JEG-3 cells for the presence of microvilli; error 
bars indicate mean ± SD. (B) Representative images from the microvillar rescue assay. Cells were stained for ezrin (red) and actin (blue) and transfected 
cells identified as those expressing the GFP-tagged construct (green). Bar, 10 µm.JCB • VOLUME 191 • NUMBER 2 • 2010   406
either PDZ1 accessibility or ezrin binding. Therefore, we first 
examined the mutants’ abilities to bind EPI64, a well-character-
ized ligand that binds PDZ1 selectively (Reczek and Bretscher, 
2001). 6xHis-tagged EPI64 was incubated with untagged EBP50 
constructs and precipitated with Talon cobalt beads, which bind 
the 6xHis tag (Fig. 9 A). All phospho-deficient and -mimetic 
mutants were able to bind EPI64 as well as wild-type EBP50, 
the biochemical properties of wild-type EBP50, the Cdc2   
phospho-deficient and -mimetic constructs S280,302A and 
S280,302D, and the PKC phospho-deficient and -mimetic con-
structs S162,339,340A and S162,339,340D.
The most likely scenario for the lack of in vivo function of 
the Cdc2 EBP50 phospho-mimetic mutant and PKC phospho-
mimetic and -deficient mutants is that they are compromised in 
Figure 7.  PKC activation and phosphorylation of EBP50 promotes microvillar rearrangement. (A) JEG-3 cells were serum starved overnight, treated with 
1 µM PMA for 30 min, then fixed and stained for endogenous EBP50 (red), ezrin (green), and actin (blue). Bar, 5 µm. (B) GFP-EBP50 wild-type and PKC 
phospho-mimetic (S162,339,340D) or -deficient (S162,339,340A) mutants were overexpressed in cells treated with PMA, stained for ezrin (red) and actin 
(blue), and their apical surface phenotype was scored. Bar, 10 µm. (C) Results from scoring JEG-3 cells for their presence of microvilli clusters; error bars 
indicate mean ± SD.407 Phospho-regulation of microvilli by EBP50 • Garbett et al.
all phospho-deficient and -mimetic EBP50 mutants bound 
equally to immobilized ezrin FERM domain and simultane-
ously bound to soluble 6xHis-EPI64 (Fig. 9 B). This eliminated 
a defect in ezrin binding, and simultaneous PDZ1 and ezrin 
indicating  that  phosphorylation  has  no  pronounced  effect   
on PDZ1 accessibility. Next, we wanted to investigate if phos-
phorylation could affect the ability of EBP50 to bind ezrin,   
or PDZ1 ligands when its tail was bound to ezrin. Wild-type and 
Figure 8.  EBP50 is an elongated monomer. (A) Untagged, full-length EBP50 was run over a Superdex 200 10/300 GL column and compared with size 
standards -amylase, alcohol dehydrogenase, and bovine serum albumin (BSA); the Stokes radius of EBP50 was calculated to be 41 Å. (B) EBP50 was run 
on sucrose gradients with size standards BSA (4.30 S), carbonic anhydrase (3.20 S), and myoglobin (2.04 S); the sedimentation coefficient was calculated 
to be 2.72 S. (C) Table summarizing gel filtration and sucrose gradient results for all PDZ and phosphorylation mutants of EBP50. The results are from at 
least two independent determinations each.JCB • VOLUME 191 • NUMBER 2 • 2010   408
Wild-type EBP50 and the Cdc2 phospho-deficient mutant were 
retained together with EPI64, although the mutant binding to 
EPI64 was less efficient. However, although both phospho- 
mimetic and the PKC phospho-deficient mutants bound -catenin 
equivalently to wild type, none were able to retain EPI64. Thus, 
phosphorylation by either Cdc2 or PKC blocks PDZ1 accessibility 
binding, as causes for their lack of in vivo function. Next, we 
examined if phosphorylation could regulate simultaneous occu-
pation of both PDZ domains in EBP50. The tail of -catenin 
has been shown to bind selectively to PDZ2 of EBP50 (Shibata 
et al., 2003), so we used immobilized GST–-catenin tail to 
precipitate a preincubated mixture of EBP50 and EPI64 (Fig. 9 C). 
Figure 9.  Phosphorylation of EBP50 by PKC or Cdc2 inhibits its ability to bind two PDZ ligands simultaneously. (A) Binding between untagged full-length 
EBP50 and 6xHis-EPI64 was tested by precipitating the 6xHis tag with Talon beads. (B) EBP50 was preincubated with soluble 6xHis-EPI64 and complexes 
recovered on FERM beads. (C) EBP50 was preincubated with soluble 6xHis-EPI64 and its ability to simultaneously bind GST–-catenin tail coupled to 
glutathione agarose was tested. For A–C, 20% of the bound fraction was run on the gels.409 Phospho-regulation of microvilli by EBP50 • Garbett et al.
cells depleted of EBP50 show no evidence of even nascent   
microvilli, thus establishing that EBP50 is involved in micro-
villar assembly. An interesting aspect of this analysis is that micro-
villi above cell junctions are less sensitive to EBP50 depletion.   
A similar phenotype has been seen in cells expressing a domi-
nant-negative ezrin construct (Crepaldi et al., 1997), suggesting 
that  the  signaling  pathways  that  drive  microvillar  assembly 
might be more potent in this region of the cell.
Using expression of RNAi-resistant GFP-EBP50 in cells 
depleted of EBP50, we have been able to investigate which bio-
chemical properties of EBP50 are necessary for its function. 
The requirement for EBP50 to bind ezrin is not surprising, as 
we have shown that either overexpressing an EBP50 construct 
lacking the ezrin binding site, or siRNA knockdown of EBP50, 
results in microvillar loss (Hanono et al., 2006). Given the re-
quirement for EBP50, we also suspected that one or both PDZ 
domains would be needed, and have shown that the function of 
PDZ2 is dispensable for the presence of microvilli. At this point, 
the required PDZ1 ligand that is necessary for microvilli re-
mains unknown. One likely candidate is EPI64, as overexpress-
ing a construct of this protein defective in EBP50 binding also 
results in loss of microvilli (Hanono et al., 2006). However, 
mislocalization of EPI64, which is a RabGAP protein and an 
effector for Arf6, away from EBP50 (Hanono et al., 2006; Itoh 
and Fukuda, 2006), may perturb the cell in additional ways that 
could indirectly result in loss of microvilli. Moreover, direct tar-
geting of EPI64 to microvilli by expressing a chimera of EPI64 
fused to the EBP50 tail did not rescue the loss of microvilli in 
EBP50-deficient cells. Although this is an artificial system, a 
similar experiment targeting the EBP50 ligand PDZK1 by chi-
meric fusion to the EBP50 tail is able to rescue microvilli   
in EBP50-deficient cells (LaLonde et al., 2010). Our working   
hypothesis is that microvilli require an unidentified ligand specific 
for EBP50’s PDZ1 domain, or in the artificial fusion system 
through binding one of PDZK1’s four PDZ domains. Our cur-
rent studies are aimed at identifying the relevant ligand.
Because EBP50 is the target of many kinases, we have   
analyzed phospho-mimetic and -deficient mutants of EBP50 in 
their ability to restore microvilli. The major in vivo site of phos-
phorylation, S290, does not appear to affect EBP50’s role in 
regulating microvilli, although it has been reported to increase 
oligomerization  (Lau  and  Hall,  2001).  PKC  phosphorylates 
S162 in PDZ2 and this reduces its affinity for CFTR (Raghuram 
et al., 2003). PKC also phosphorylates S339 and S340, and 
phosphorylation of these sites has been shown to inhibit the 
tail–PDZ2 interaction and thereby enhance the binding capacity 
for CFTR (Li et al., 2007). We have found that an EBP50 mu-
tant where we have added a C-terminal alanine to eliminate the 
EBP50  tail–PDZ2  intramolecular  association  is  functionally   
capable of microvilli assembly in our assay, implying that the loss 
of tail–PDZ2 interaction is not the reason our PKC site phos-
pho-mimetic mutant does not support microvilli. Additionally, 
and  quite  surprisingly,  both  the  EBP50  S162,339,340A  and 
S162,339,340D mutants were unable to function in this assay. 
Preliminary  experiments  with  these  individual  sites  mutated 
gave intermediate results in vivo, and their biochemical properties 
have not been fully analyzed (unpublished data). Remarkably, 
specifically when PDZ2 is occupied. Additionally, mutation of 
the PKC sites to alanine also blocks the accessibility of PDZ1 
when PDZ2 is occupied.
Cdc2 and PKC phosphorylation and PDZ2 
occupancy coordinately regulate the 
microvillar assembly function of EBP50
Our biochemical results show that in the context of Cdc2 or PKC 
phospho-mimetic mutations, or the PKC phospho-deficient mu-
tation, accessibility of PDZ1 in EBP50 is inhibited by the occu-
pancy of PDZ2. If this in vitro biochemical result is the cause of 
the inability of the mutants to function in microvillar assembly, 
introducing an additional mutation to inactivate PDZ2 should 
render the PDZ1 accessible and the proteins functional. We 
therefore mutated the PDZ2 domain in these mutants and as-
sayed their ability to restore microvilli in siEBP50-treated cells 
(Fig. 10). Strikingly, mutation of the PDZ2 domain was able to 
reverse the defect in microvillar formation for both the Cdc2 
site phospho-mimetic and the PKC site phospho-mimetic and   
-deficient mutants (Fig. 10, A and B). Collectively, these results 
suggest that EBP50 phosphorylation by either PKC or Cdc2   
inhibits simultaneous binding to both PDZ domains and that   
in cells the presence of a PDZ2-binding partner acts to inhibit 
PDZ1 binding in this phosphorylated pool of EBP50.
Discussion
Microvilli are striking and dynamic morphological features of 
the apical aspect of polarized epithelial cells, yet little is known 
about  how  the  cell  assembles  and  regulates  their  presence.   
Because both the ezrin and EBP50 knockout mice have defective 
intestinal epithelial microvilli (Morales et al., 2004; Saotome 
et al., 2004), these proteins are potential candidates for regulat-
ing microvilli. Ezrin’s activity is well known to be regulated by 
phosphorylation, and recent studies have indicated that the ki-
nase Mst4 is critical in activating it at the apical aspect of epi-
thelial cells (Bretscher, 2009; ten Klooster et al., 2009). EBP50 
has been shown to bind multiple ligands through its PDZ domains 
to either scaffold functionally related proteins (Takahashi et al., 
2006) or regulate the presence of proteins at the cell surface, 
such as EGFR and CFTR (Short et al., 1998; Lazar et al.,   
2004). Either of these activities could potentially contribute to   
microvillar biogenesis. Because EBP50 is the target of several   
kinases, much effort has been devoted to investigating their 
regulatory function. Thus, it has been suggested that EBP50 
phosphorylation by GRK6A regulates its oligomerization to 
facilitate cellular signaling complexes (Lau and Hall, 2001; 
Shenolikar and Weinman, 2001), and PKC phosphorylation 
modulates accessibility to its second PDZ domain (Li et al., 
2007). Here we investigate one major function of EBP50, its 
contribution to the presence of microvilli on epithelial cells, 
and further characterize its biophysical properties in detail, as 
well as biochemical and functional consequences of phosphory-
lation by PKC and Cdc2.
We first investigated which aspect of the microvillar life 
cycle is affected by EBP50 depletion. Scanning electron mi-
croscopy and live-cell imaging with ezrin-GFP both show that JCB • VOLUME 191 • NUMBER 2 • 2010   410
Figure 10.  Mutation of PDZ2 restores the ability of Cdc2 and PKC site EBP50 phospho-mutants to form microvilli. (A) Results from scoring JEG-3 cells for 
the presence of microvilli; error bars indicate mean ± SD. (B) Representative images from the microvillar rescue assay. Cells were stained for ezrin (red) 
and actin (blue) and transfected cells identified as those expressing the GFP-tagged construct (green). Bar, 10 µm.
simultaneous  coexpression  of  these  phospho-mimetic  and   
-deficient mutants restored microvilli. Whether this indicates   
a requirement for phosphorylation recycling, or of differential 
binding of distinct ligands to the phospho-mimetic and -deficient 
forms is not clear. However, the physiological relevance of PKC 
site phosphorylation is strongly suggested by a similar clustered 411 Phospho-regulation of microvilli by EBP50 • Garbett et al.
In summary, EBP50 has previously been shown to be an 
important scaffolding protein in bringing specific membrane   
ligands together, or retaining them at the cell surface. Here we 
show that EBP50 is also a point of regulation for microvilli, and 
have  elucidated  its  functional  requirements  and  regulatory 
mechanisms in this process. More than just a “simple scaffold-
ing”  protein,  EBP50  is  emerging  as  an  important  nexus  for   
coordinating structure with function at the apical aspect of inter-
phase polarized epithelial cells.
Materials and methods
Antibodies and reagents
Antisera and affinity-purified antibodies against human ezrin and EBP50 
were described previously (Bretscher, 1989; Reczek et al., 1997). The 
mouse antibody against -tubulin was purchased from Sigma-Aldrich. The 
mouse antibody against ezrin developed at the National Cancer Institute 
(Bethesda, MD) was obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the National Institute of Child Health 
and Human Development and maintained by the Department of Biology at 
The University of Iowa (Iowa City, IA). All Alexa Fluor–conjugated secondary 
antibodies, YOPRO-1 DNA stain, and Alexa Fluor 660–conjugated phal-
loidin were purchased from Invitrogen. IRDye 680– and 800–conjugated 
secondary antibodies were obtained from LI-COR Biosciences. The siRNAs 
targeting human EBP50 (5-CGGCGAAAACGTGGAGAAG-3) and Lucif-
erase  GL2  (5-CGUACGCGGAAUACUUCGA-3)  were  obtained  from 
Thermo Fisher Scientific and Applied Biosystems.
Cell culture and transfection
JEG-3 cells (American Type Culture Collection) were maintained in a 5% 
CO2 humidified atmosphere at 37°C in MEM with 10% FBS (Invitrogen). 
Cells were transfected with polyethylenimine (PEI; Polysciences, Inc.) and 
DNA as described previously (Hanono et al., 2006). For microvillar rescue 
assays, cells were first transfected with 1–2 µg of DNA at low confluence, 
allowed to recover for 24 h, then transfected again with 10 nM of siRNA 
using Lipofectamine RNAiMax, allowed to grow for another 48 h, then pro-
cessed for immunofluorescence and counting, or Western blot analysis. 
Transfected  cells  expressed  RNAi-resistant  GFP-tagged  EBP50  at  levels   
70–300%  of  endogenous  in  nonsiRNA–treated  cells  as  determined  by 
quantitative Western blot. For mitotic arrest studies cells were incubated 
with 50 ng/ml nocodazole (Sigma-Aldrich) ± 2 µM roscovitine (Sigma- 
Aldrich) for 18–20 h before preparation for analysis. For PKC activation ex-
periments, cells were serum starved overnight, then treated with 1 µM PMA 
for 30 min before preparation for analysis.
DNA constructs
All EBP50 constructs were created in pEGFP-C2 (Takara Bio Inc.), pMal-
C2X  (New  England  Biolabs,  Inc.),  and  pE-SUMO  (LifeSensors  Inc.). 
TagRFPT-EBP50 constructs were created by PCR from a vector expressing 
TagRFPT that was generously provided by Roger Tsien (University of Cali-
fornia, San Diego, La Jolla, CA; Shaner et al., 2008). Ezrin-GFP was cre-
ated in pEGFP-N2 (Takara Bio Inc.). The -catenin tail cDNA was obtained 
from Thermo Fisher Scientific and tail residues 695–781 were inserted into 
pGEX-6P1 (GE Healthcare) using PCR. Untagged ezrin FERM in pQE16 
(QIAGEN)  was  described  previously  (Reczek  et  al.,  1997).  Full-length 
6xHis-tagged EPI64 was created in pFastBac-HT (Invitrogen).
Western blotting and immunofluorescence
Protein samples were separated by SDS-PAGE and transferred to Immobi-
lon-FL (Millipore). All Western blots were imaged using an Odyssey infra-
red imaging system (LI-COR Biosciences). For immunofluorescence, cells 
grown on glass coverslips were fixed in 3.7% formaldehyde/PBS for 10 min 
at room temperature. Cells were permeabilized in 0.2% Triton X-100/ 
PBS for 5 min at room temperature, rinsed in PBS, and incubated in pri-
mary antibodies in 3% FBS in PBS. After washing in PBS, secondary anti-
bodies and additional markers (phalloidin, DNA counterstain) were added 
in 3% FBS in PBS. After further washing in PBS, coverslips were mounted 
onto glass slides using Vectashield (H-1000; Vector Laboratories), and im-
ages were then acquired on a CSU-X spinning disk microscope (Intelligent 
Imaging Innovations) with spherical aberration correction device, 63x 1.4 
NA objective on an inverted microscope (model DMI6000B; Leica), and 
an HQ2 CCD camera (Photometrics) using Slidebook 5.0 (Intelligent Imaging 
microvillar phenotype in cells treated with the PKC activator 
PMA, and expressing either wild-type or the phospho-mimetic 
construct, but not the phospho-deficient mutant.
The two Cdc2 sites, S280 and S302, become highly phos-
phorylated in mitosis (He et al., 2001). Expression of the 
S280,302D phospho-mimetic mutant was not able to support 
microvilli, whereas the corresponding phospho-deficient forms 
were. As these sites are located well downstream of the PDZ   
domains, this was an unexpected finding. Our results show that 
microvilli on mitotic cells are much shorter than those on inter-
phase cells and do not have the same requirement for EBP50. It   
appears, therefore, that in mitotic cells the regulation conferred 
by EBP50 has been inactivated by phosphorylation to allow cells 
to assemble structurally different microvilli, but that still contain 
ezrin. Despite not being required, EBP50 is nevertheless present 
in mitotic cell microvilli, presumably because the phosphory-
lated EBP50 still retains the ability to bind active ezrin.
Our  biochemical  and  functional  analyses  of  the  EBP50 
Cdc2 phospho-mimetic and PKC phospho-mimetic and -deficient 
mutants have uncovered a novel mechanism of regulation explain-
ing why these constructs cannot support the assembly of micro-
villi in interphase cells. All of these mutants are indistinguishable 
in vitro from the wild-type protein in their ability to bind ezrin 
alone, or the PDZ1-specific ligand EPI64 alone, or simultaneously 
to both ezrin and EPI64. However, just those mutants unable to 
support microvillar assembly in vivo are also unable to bind a 
PDZ1 ligand in vitro when PDZ2 is occupied. If this mechanism 
operates in vivo, we predicted that additionally inactivating PDZ2 
should restore the ability of these mutants to support microvillar 
assembly, and indeed this is precisely what we found. These re-
sults reinforce the notion that PDZ1 has to bind a ligand to func-
tion in microvillar biogenesis. More significantly, they have 
uncovered an in vivo regulation of PDZ1 accessibility by occu-
pancy of PDZ2, implying that there is a sufficient level of a PDZ2 
ligand in vivo to inhibit binding to PDZ1. Thus, EBP50 is regu-
lated both by phosphorylation and PDZ2 occupancy.
Our biophysical studies on purified wild-type and phospho- 
mimetic and -deficient mutants show that they are highly elon-
gated monomeric proteins in solution. Our analyses have been 
performed at concentrations of EBP50 many times higher   
(2–4 mg/ml) than is encountered in vivo, so the lack of a tendency 
to form oligomers in vitro suggests that EBP50 is unlikely to 
form intermolecular associations in vivo. However, this does not 
exclude the possibility that other proteins could bridge individual 
EBP50 monomers to generate hetero-oligomeric species in vivo, 
which may in part explain some of the past results involving pre-
cipitation out of cell extracts (He et al., 2001; Shenolikar et al., 
2001; Fouassier et al., 2005).
Several studies have suggested that EBP50 is regulated by 
its oligomeric state. Two properties of EBP50 may have con-
tributed to some of these conclusions. First, it was not initially 
appreciated that the tail of EBP50 can bind PDZ2 intramolecu-
larly, so some overlay experiments may have been misinter-
preted. Second, being unaware of the high asymmetry of EBP50 
might have led some authors to misinterpret gel filtration stud-
ies, where EBP50 runs at a position typical for a globular pro-
tein of 100 kD, exactly twice the size it runs on SDS-PAGE.JCB • VOLUME 191 • NUMBER 2 • 2010   412
and 50 mM Tris, pH 8.0, and then 6xHis-EPI64 was eluted in wash buffer 
with 1 M imidazole.
Gel filtration and sucrose gradients
1–2  mg  of  untagged  full-length  EBP50  was  run  over  a  superdex  200 
10/300 GL column on an AKTA FPLC (GE Healthcare) in 150 mM NaCl 
and 10 mM Tris, pH 7.4, with 1 mM DTT. Stokes radii were calculated   
as described previously (Begg et al., 2001). Full-length EBP50 was run on   
5–20% sucrose gradients with size standards BSA (4.3 S), carbonic anhy-
drase (3.2 S), and myoglobin (2.04 S) in a rotor (model SW60Ti; Beck-
man Coulter) at 50,000 rpm for 26 h at 4°C. Fractions were collected 
manually, run out by SDS-PAGE, and stained with IRDye blue protein stain 
(LI-COR Biosciences) for band densitometry and sedimentation coefficient 
calculation. Frictional ratios were calculated from ƒ/ƒo = Rs(4N/3ῡMr)
1/3, 
where Rs is the experimentally determined Stokes radius, N is Avogadro’s 
number, ῡ is the partial specific volume (taken to be 0.74 cm
3/g for pro-
tein), and Mr is the calculated molecular mass.
In vitro–binding assays
For EBP50-tail to ezrin-FERM binding assays, 7 µg of MBP-EBP50 tail con-
structs were incubated with 7 µl of ezrin FERM-CNBr bead slurry (coupled to 
be 2 µg/µl on the beads) in 300 mM NaCl, 0.1% Triton X-100, 5% glycerol, 
and 20 mM Tris, pH 7.4, for 1 h at 4°C, washed, and then boiled in SDS 
sample buffer. Samples were run on SDS-PAGE, stained with IRDye blue pro-
tein stain and scanned using an Odyssey infrared imaging system.
All other binding assays were incubated in binding buffer (150 mM 
NaCl, 0.1% Triton X-100, 5% glycerol, and 25 mM Tris, pH 7.4) at 4°C, 
washed, and boiled in sample buffer. For experiments testing the ability of 
EBP50 to bind soluble EPI64 simultaneously to either ezrin FERM-CNBr 
beads or GST–-catenin tail beads, EBP50 and EPI64 were preincubated 
for 20 min on ice before addition of the beads. Binding conditions were 
set so the molarity of all proteins (both soluble and coupled to beads) were 
kept equal at 500 nM. Beads were boiled in SDS sample buffer and 20% 
of the sample was run on SDS-PAGE and transferred to Immobilon-FL mem-
brane for Western blot analysis.
Online supplemental material
Fig. S1 shows Western blots of lysates from microvillar rescue experiments. 
Fig. S2 shows that an EPI64-EBP50 tail chimera is unable to restore micro-
villi in siEBP50-treated cells. Fig. S3 shows that phosphorylation of EBP50 
by GRK6A does not affect its ability to form microvilli. Fig. S4 shows that 
EBP50 is phosphorylated by Cdc2 during mitosis. Fig. S5 shows purifi-
cation of SUMO-EBP50. Video 1 shows normal microvilli in control cells.   
Video 2 shows defects in microvilli formation in siEBP50 cells. Video 3 shows 
RNAi-resistant EBP50 restores microvilli in siEBP50-treated cells. Video 4 
shows that the RNAi-resistant EBP50-PDZ1/2 mutant is unable to form micro-
villi in siEBP50-treated cells. Video 5 shows that RNAi-resistant EBP50-
S280,302D is unable to form microvilli in siEBP50-treated cells. Video 6 
shows that RNAi-resistant EBP50-S162,339,340D is unable to form micro-
villi in siEBP50-treated cells. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.201004115/DC1.
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Innovations). Images were also processed using Slidebook 5.0 (Intelligent 
Imaging Innovations).
Scoring the apical surface phenotype of transfected cells
Transfected JEG-3 cells were scored as described previously (Hanono   
et al., 2006). In brief, cells were stained for ezrin and F-actin to indicate 
the  apical  membrane  phenotype,  whereas  the  GFP-tagged  constructs 
marked transfected cells. At least 250 cells were counted for each condi-
tion in each of three replicates. Cells were scored as having normal micro-
villi, no microvilli, lacking/few microvilli, or ruffles (with PMA treatment 
cells were also scored as having microvilli clusters).
Scanning electron microscopy
JEG-3 cells were fixed by removing cell culture media and rapid addition of 
2.5% glutaraldehyde in PO4 buffer for 45 min. After fixation, cells were rinsed 
three times in PO4 buffer and dehydrated in a graded ethanol series. To mini-
mize drying artifacts samples were first dehydrated in 20% ethanol and then 
increasing amounts for 10 min each followed by two changes in 100% for   
10 min each. After dehydration, samples were critical point dried and sputter 
coated with gold and palladium. Samples were imaged on a scanning elec-
tron microscope (Stereoscan 440; Leica) operated at 25 kV; images were ob-
tained at 4,000 and 20,000x and processed with ImageJ.
Live-cell imaging
Transfected  JEG-3  cells  grown  in  35-mm  glass-bottom  dishes  (MatTek 
Corp) were washed twice in PBS and then maintained in low sodium bi-
carbonate phenol red–free MEM (Sigma-Aldrich) supplemented with 25 mM 
Hepes, pH 7.4, with 10% FBS and glutamax (Invitrogen). Live cells were 
imaged by time-lapse microscopy on a CSU-X spinning disk (Intelligent 
Imaging Innovations) with spherical aberration correction device, 63x 
1.4 NA objective on an inverted microscope (DMI6000B; Leica) and 
QuantEM EMCCD camera (Photometrics) at 37°C in an environmental 
chamber (Okolab) controlled by Slidebook 5.0 (Intelligent Imaging Inno-
vations). Movies were processed using Slidebook 5.0 (Intelligent Imaging 
Innovations) and ImageJ.
Purification of recombinant proteins
Ezrin FERM was purified as described previously (Reczek et al., 1997).   
In brief, induced cells were lysed in 180 mM KH2PO4, pH 7.0, with complete 
protease inhibitor (Roche), lysed by sonication (Branson Ultrasonics), cen-
trifuged and run over a hydroxyapatite column (Pall), and eluted by linear 
gradient of 180–800 mM KH2PO4. Ezrin FERM–containing fractions were 
pooled and dialyzed against 20 mM MES, 150 mM NaCl, pH 6.7, and 
applied to an S-sepharose column (GE Healthcare) and eluted in a linear 
gradient of 0.15–1.0 M NaCl. To conjugate purified FERM to cyanogen 
bromide (CNBr)–activated Sepharose (Sigma-Aldrich) it was dialyzed into 
C Buffer (0.1 M NaHCO3 and 0.5 M NaCl, pH 8.3) and then added to 
hydrated CNBr beads for a final concentration of 2 mg/ml on the resin 
overnight. Beads were then washed, and blocked in 0.25 M glycine, pH 
8.0, overnight. Beads were washed again, and then stored as a 50% 
slurry in H buffer (50 mM Tris, and 150 mM NaCl, pH 7.4).
Maltose-binding protein (MBP) fused to the last 39 amino acids of 
the EBP50 tails with various mutations were purified as described previ-
ously (Finnerty et al., 2004). In brief, induced cells were lysed in PBS with 
1 mM DTT and complete protease inhibitor by sonication, centrifuged and 
run over amylose resin column (New England Biolabs, Inc.), washed with 
PBS, and then eluted in PBS with 10 mM maltose.
Bacterical pellets induced to express GST–-catenin tail were lysed 
in 150 mM NaCl, 20 mM Tris, pH 7.4, 0.1% BME, and 0.1% Triton X-100 
with complete protease inhibitor by sonication, centrifuged and added to 
hydrated glutathione agarose (Sigma-Aldrich), washed, and left as a 50% 
slurry for binding assays.
SUMO-EBP50  constructs  were  purified  as  described  previously 
(LaLonde et al., 2010). In brief, induced bacterial pellets were lysed in bind-
ing buffer (20 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole, 
pH 7.4, and 1% Triton X-100) by sonication, centrifuged and run over a His 
gravitrap column (GE Healthcare), washed, and eluted in elution buffer   
(20 mM sodium phosphate, 500 mM NaCl, and 500 mM imidazole,   
pH 7.4). Eluate was dialyzed into binding buffer, cleaved with 6xHis-Ulp1 for 
40 min at 30°C to remove the SUMO tag, and then run over another His 
gravitrap column and flowthrough containing untagged EBP50 was collected 
and dialyzed into 150 mM NaCl, 10 mM Tris, pH 7.4, with 1 mM DTT.
6xHis-tagged EPI64 expressed in SF9 insect cells was lysed in 150 mM 
NaCl, 1% NP-40, and 50 mM Tris, pH 8.0 with complete protease inhibi-
tor by sonication, centrifuged, and incubated with Ni
2+-NTA agarose   
(QIAGEN) for 1 h. Beads were washed in 500 mM NaCl, 5 mM imidazole, 413 Phospho-regulation of microvilli by EBP50 • Garbett et al.
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